[HTML][HTML] Bezlotoxumab (zinplava) for Clostridium difficile infection: The first monoclonal antibody approved to prevent the recurrence of a bacterial infection

Y Lee, WI Lim, CI Bloom, S Moore… - Pharmacy and …, 2017 - ncbi.nlm.nih.gov
Y Lee, WI Lim, CI Bloom, S Moore, E Chung, N Marzella
Pharmacy and Therapeutics, 2017ncbi.nlm.nih.gov
According to the Centers for Disease Control and Prevention (CDC), Clos tridium difficile
(Figure 1) is the most common microbial cause of health careassociated infections in US
hospitals, costing up to $4.8 billion each year in excess health care costs for acute-care
facilities alone. Older Americans are especially vulnerable to this potentially deadly
diarrheal infection. The CDC has reported that two-thirds of health careassociated C. difficile
infections (CDI) occur in patients 65 years of age or older. 1 CDI can also affect individuals …
According to the Centers for Disease Control and Prevention (CDC), Clos tridium difficile (Figure 1) is the most common microbial cause of health careassociated infections in US hospitals, costing up to $4.8 billion each year in excess health care costs for acute-care facilities alone. Older Americans are especially vulnerable to this potentially deadly diarrheal infection. The CDC has reported that two-thirds of health careassociated C. difficile infections (CDI) occur in patients 65 years of age or older. 1 CDI can also affect individuals in the community setting. 2, 3 In addition to hospitalization and advanced age, risk factors for
ncbi.nlm.nih.gov